GLOW vs KLOW: What the Extra “K” Actually Means
KLOW is GLOW plus a fourth peptide, KPV. The two blends share three components, but neither has whole-formulation studies, and suppliers are not required to use the same ratios. This guide compares the evidence tier of each component, explains why the names are not formulations, and links to blend calculators that work from your actual vial's amounts.
Two peptide blends, one letter apart. When "KLOW" started appearing in the same threads as GLOW, plenty of people assumed it was a typo. It isn't: KLOW is a real research blend, and the K stands for a fourth peptide. Here is what actually differs between the two, what the evidence supports, and what nobody can honestly claim either way.
Quick refresher on GLOW
GLOW is a three-peptide research blend:
- GHK-Cu, the copper peptide found naturally in plasma, studied for decades in skin and wound contexts. See our GHK-Cu compound guide.
- BPC-157, a 15-amino-acid peptide based on a gastric juice protein fragment, studied mostly in rodents for tissue and gut repair. See BPC-157: what the research actually says.
- TB-500, a synthetic fragment of thymosin beta-4, studied in animals for healing. See TB-500: what the research actually says.
What the K in KLOW stands for
KPV. KLOW is GLOW plus KPV: the same three peptides with a fourth added.
KPV is a three-amino-acid fragment of alpha-MSH, a hormone the body makes naturally. Researchers isolated the final three amino acids of that hormone because early work suggested the fragment might carry some anti-inflammatory activity on its own. Most of the KPV research is preclinical — cell studies and animal models, especially rodent models of colitis. There is also interest in skin, since alpha-MSH itself is involved in skin biology. See KPV: the little peptide gut-health Reddit is whispering about.
GLOW vs KLOW, side by side
| GLOW | KLOW | |
|---|---|---|
| Components | GHK-Cu, BPC-157, TB-500 | GHK-Cu, BPC-157, TB-500, KPV |
| The extra ingredient | — | KPV, a 3-amino-acid alpha-MSH fragment |
| GHK-Cu evidence | Decades of skin and wound research, including some human topical studies | Same |
| BPC-157 evidence | Large body of rodent studies; very little human data | Same |
| TB-500 evidence | Animal studies; very limited human data specific to the fragment | Same |
| KPV evidence | — | Mostly preclinical: cell and animal models of inflammation and gut injury |
| Whole-blend studies | None published | None published |
Formulation variability: the names are community names
"GLOW" and "KLOW" are community names, not standardized formulations. Nothing requires two suppliers to use the same component ratios, the same total peptide per vial, or even the same ingredient list under the same label.
That has practical consequences:
- The ingredient statement on the label — and the batch-specific COA behind it — is the only reliable statement of what is in the vial.
- A four-peptide blend is four opportunities for a vendor to shortchange you. If the COA doesn't cover the blend as sold, you can't verify the KPV is in there, or at what ratio.
- Any concentration math must start from the actual amounts in your vial, not from a name.
Our blend calculators are built around that last point. The GLOW blend calculator and KLOW blend calculator never assume a composition: you enter each component's amount exactly as labeled on your vial, and the tool computes each component's concentration, its share of the blend, and the amount present in any volume you draw, with component totals reconciled against the whole.
Evidence and unanswered questions
Neither blend has published research as a whole. The studies that exist are on the individual peptides, and they are not evenly distributed:
- GHK-Cu has the deepest literature, including some human topical studies in skin contexts.
- BPC-157 has a large body of rodent work and very little human data.
- TB-500 has animal studies; human data specific to the fragment is limited.
- KPV is the least studied of the four — mostly cell and animal models.
And the questions an honest reader should keep open:
- Do the components interact in solution, for better or worse? Nobody has published on it.
- Does the blend's composition remain stable across the vial's stated shelf life? Blend-specific stability data is rarely published.
- Is there any human evidence for either blend as a whole? No.
So the honest framing is: KLOW is not "GLOW but better." It is GLOW plus one additional, less-studied peptide. Whether it belongs in your research depends on the questions you are asking, and a label cannot settle it.
Also worth knowing
Both blends are research compounds. None of the four peptides is FDA-approved for any human use, and BPC-157 and TB-500 are on the WADA prohibited list. Vendors like Exactide sell GLOW, KLOW, and the individual peptides as research-grade material with batch-specific COAs — verify the blend composition the same way you would for a single peptide.
The short version
- KLOW = GLOW + KPV, a small alpha-MSH fragment studied mostly in preclinical inflammation and gut models.
- Neither blend has whole-formulation studies; evidence tiers differ by component.
- Names are not formulations: verify composition from the label and batch-specific COA, and run concentration math from your actual vial using the GLOW blend calculator or KLOW blend calculator.
Get a new guide every week.
Subscribe free and the Beginner's Guide to Peptide Research is yours instantly.